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Interleukin-1 Induces Tumor Necrosis Factor (TNF) in Human Peripheral Blood 
Mononuclear Cells In Vitro and a Circulating TNF-like Activity in Rabbits
Takashi Ikejima, Seijiro Okusawa, Pietro Ghezzi, From the Department of Medicine, New England Medical Center
Jos W. M. van der Meer, and Charles A. Dinarello Hospitals and Tufts University School of Medicine,
Boston, Massachusetts
Recombinant human interleukin-1 (IL-1), injected into rabbits, induces the synthesis of endog­
enous IL-1. Also, IL-1 induces its own gene expression and synthesis in human peripheral blood 
mononuclear cells (PBMC). In this study, tumor necrosis factor-a ('TNF-a) production by PBMC 
of 40 individuals stimulated with IL-1 a or IL-1/3 was determined by specific radioimmunoassay 
(RIA). After 3 h of PBMC incubation with IL-1, TNF^a mRNA was detected. IL - la  stimulated 
both IL-1/3 and TNF-a, but there was no correlation in the amount of T N F a  or IL-1/3 synthesized 
in the PBMC of 29 individuals. IL-l-stimulated adherent cells produced ^50% more TNF^a 
than did unfractionated PBMC. Coincubation with interferon-7 (IFN-7 ) did not change the 
amount of IL-l-induced TNF1«, whereas in the same culture IFN-7 inhibited (>70%) IL-1- 
induced IL-1 production. Endogenous pyrogen and TNIMike activity were detected in the sera 
of rabbits 3.5 h after injection of either IL-1 a: or -1(3. These studies demonstrate that IL-1 induced 
TNF1« production in vivo and in vitro.
Homogenously pure preparations of either interleukin-1 a  
(IL-1 a) or interleukin-1 (3 (IL-1 (3) have been shown to produce 
typical endogenous pyrogen fever [1-4]. Thé two types of 
IL-1 have been cloned from human, rabbit, and murine cells 
[5-9]. Both forms of recombinant IL-1 have been used to 
confirm that IL-1 is a potent inducer of several in vivo re­
sponses [9-11].
Tumor necrosis factor-a: (TNF-a) is another cytokine that 
is an endogenous pyrogen [12]. TNF-a is identical to cachec- 
tin [13]. Human [14] and mouse [15] TNF-a do not have 
significant amino acid sequence homology with any IL-1 a  or 
-10, and the two cytokines have distinct receptors. However, 
TNF-a and IL-1 share many biologic properties, and their 
gene expression occurs with similar stimuli. The two cytokines 
also share a common repeating nucleotide sequence in the 
3' untranslated region [16]. In addition to the induction of fe­
ver, IL-1 and TNF induce synovial collagenase and prosta­
glandin E 2 (PGE2) [17], increase hepatic acute-phase protein 
synthesis [18], activate endothelial cells [19], decrease hepatic 
albumin synthesis [18, 20], inhibit lipoprotein lipase activity 
[21, 22], stimulate cfos  and cm ic  mRNA [23], and are cyto­
toxic for some tumor cell lines [24]. Treatment of human 
fibroblasts with IL-1 or TNF-a induces synthesis of seven poly­
peptides as identified by computer-based analysis of two- 
dimensional gels [25].
Received 21 August 1989; revised 22 January 1990.
Grant support: AI-15614 (National Institutes of Health).
Reprints and correspondence: Dr. Charles A. Dinarello, Department of 
Medicine, Division of Geographic Medicine and Infectious Diseases, New 
England Medical Center Hospitals, 750 Washington St., Boston, MA 02111.
The Journal of Infectious Diseases 1990;162:215-223 
© 1990 by The University of Chicago. All rights reserved.
0022-1899/90/6201 -0033$01.00
Previously, we have demonstrated that TNF-a induces cir­
culating IL-1 in rabbits and synthesis from human peripheral 
blood mononuclear cells (PBMC) in vitro [12]. The same has 
been observed using human endothelial cells [26]. We recentiy 
showed that the expression of both IL-1 a  and -1 ¡3 genes in 
human PBMC [27], human endothelial cells [28], and smooth 
muscle cells [29] is stimulated by IL-1 itself. In this study 
we test the possibility that IL-1 induces TNF-a in human 
PBMC and that IL-1 induces circulating TNF-like activity in 
the rabbit. Because IL-l-induced IL-1 production is inhibited 
by interferon-7 (IFN-7 ) [30], we examined the effect of IFN- 
7  on IL-l-induced TNF-a production.
Materials and Methods
IL-1, TNF-a, and IFN-7 . Recombinant human (rh) IL-1 a  and -1/3 
(gifts of Dr. Alan Shaw, Glaxo Institute for Molecular Biology, 
Geneva, Switzerland) had specific activities of 6.1 and 5.3 x  107 
units/mg, respectively, as measured with thymocytes in a costimu­
lation assay. IL-1 preparations contained <100 pg of lipopolysac- 
charide (LPS)/mg of protein as measured by the Limulus amebocyte 
lysate test (Cape Cod Associates, Woods Hole, MA), which has a 
limit of detection of 15 pg/ml LPS. The source of rhTNF-a has been 
previously described [12]. IFN-7 , produced in Escherichia coli, was 
the same as used in previous studies [30]. LPS from E. coli was 
purchased from Sigma Chemical (St. Louis).
Specific radioimmunoassays for human TNF-a and IL-1 (3. Methods 
for radioimmunoassay (RIA) for human TN F-a [31] and IL-1/3 [32] 
have been reported. The sensitivities of these RIAs were 40 and 80 
pg/ml, respectively.
Human PBMC. Blood from healthy male volunteers was drawn 
into heparinized syringes. PBMC, separated by centrifugation over 
ficoll-hypaque (Pharmacia, Piscataway, NJ; Winthrop Laboratories, 
New York), were suspended at 5 x 106/ml in RPMI 1640 medium 
(M. A. Bioproducts, Walkersville, MD) that had been subjected to
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ultrafiltration to remove endotoxins as previously described [33]. 
Heat-inactivated autologous human serum (2%) was added, and 100 
n\ of this suspension was placed in flat-bottomed 96-well microtiter 
plates containing an equal volume of IL-1 diluted in RPMI 1640 
medium.
In some experiments, IFN -7  (1-1000 units/ml) was added to the 
cell culture. In other experiments, microtiter plates were coated with 
autologous sera at room temperature overnight. After removing the 
sera, 100 /xl of PBMC suspension was added and incubated at 37°C 
for 1.5 h in a humidified 5% C 0 2 atmosphere. Nonadherent cells 
were removed by washing three times in RPMI 1640 medium, and 
200 /xl of RPMI 1640 medium containing 1% autologous serum and 
IL-1 (a or (3) was added to each well. More than 90% of adherent 
cells were positive for «-naphthyl acetate esterase activity as de­
tected by the cytologic demonstration kit (Sigma). These cells were 
incubated for various time periods. Culture supernatants or lysates 
prepared by three freeze-thaw cycles 132] were assayed for TNF-« 
and IL-1/3.
Rabbit antihuman antibodies. Rabbits were initially immunized 
with rhIL-1 (a  or (3) by multiple intradermal injections in complete 
Freunds adjuvant. Six weeks later, the animals were boosted by four 
weekly intradermal injections of IL-1 in incomplete Freunds adju­
vant, followed by four weekly intravenous injections. Serum was 
precipitated in 40% saturated ammonium sulfate, and these immu­
noglobulin preparations neutralized IL-1 activity as measured in the 
D10.G4.1 cell bioassay [27].
Isolation o f human RNA and Northern blot analysis. Human 
PBMC were suspended in cold ultrafiltered RPMI 1640 medium 
with 1% human AB serum at 2.5 x 10(’ cells/nil in 50-ml polypro­
pylene centrifuge tubes (Falcon, Oxnard, CA). Cells were stimu­
lated with 100 ng/ml IL-1«, and tubes containing 30 ml of the cell 
suspension were gently rotated at 0.25 rpm inside a bottomless roller 
bottle at 37°C for 3 h. Cells were collected after centrifugation at 
500 g , and the cell pellet was lysed in guanidine isothiocyanate. To­
tal RNA was recovered after centrifugation through CsCl. After 
ethanol precipitation, the RNA content was measured spectropho- 
tometrically using an absorbance of 2601280 nm.
RNA samples (15 /xg each) were subjected to electrophoresis in
1.2% agarose (Bethesda Research Laboratories, Rockville, MD) con­
taining 2.2 M  formaldehyde. After examining the ethidium-stained 
gel directly under ultraviolet light irradiation (260-360 nm) at the 
end of the electrophoresis, the RNA was transferred to nylon mem­
branes (Amersham, Arlington Heights, IL) and fixed by ultraviolet 
irradiation. Membranes were probed with 32P-labeled 1.1-kilobase 
(kb) fragment (5 .9/1 to Pstl) of full-length cDNA clone of the human 
IL-1/3 precursor [5] or the human TNF-« cDNA fragment. The lat­
ter probe (Du Pont Pharmaceuticals, Wilmington, DE) was a 
470-base pair (bp) fragment (bp 381-854) of the full-length cDNA. 
32P-labeled probes were prepared using a random primed DNA 
labeling kit (Boehringer Mannheim, Mannheim, FRG).
The specific activity of the resulting DNA was M  x 10K counts 
per minute (cpm)/^ig. Since mRNAs coding for human TNF-« and 
IL-113 were detected at the same loci (1.6 kb) in Northern blot analy­
ses, hybridization with the TNF probe was done first, followed by 
the hybridization with the IL-1 (3 probe. Strong stripping solution con­
taining 2.5% formamide, 0.5 X standard saline citrate, 0.05 x Den- 
hardt’s solution, 5 x  10_J M  EDTA, and 0.5% sodium dodecyl 
sulfate was used for stripping the radioactive cDNA probe for TNF-«.
Rabbit studies. IL-1« and -1 (3 were diluted in saline and injected 
into the lateral ear veins of New Zealand white female rabbits weigh­
ing 2.5-3.0 kg. Rectal temperatures were monitored at 1-min inter­
vals using YSI flexible thermistors (Yellow Springs Instrument Co., 
Yellow Springs, OH) and were recorded on a DR-1A Digistrip II 
apparatus (Kaye Instruments, Bedford, MA). For passive transfer 
experiments, heparinized blood was collected from the ear arteries 
during the second febrile peak. The plasma (10 ml) was separated, 
warmed to 37°C, and injected into the ear veins of recipient rabbits. 
Rectal temperatures in these rabbits were recorded for 1.5-2.5 h. 
Serum samples were collected at the same time and were used in 
the bioassay of TNF-like activity. To determine the time course of 
the appearance of TNF-like activity in the circulation, other rabbits 
were bled 3 and 5 h after intravenous injection (9 ¿¿g/kg) of IL-1 
(« or (3).
Bioassay fo r  TNF-like activity in the rabbit. TNF activity was 
measured by its cytotoxicity for the tumorigenic murine fibroblast 
L929 (ATCC CCL1: American Type Culture Collection, Rockville, 
MD) 134]. Briefly, L929 cells were seeded in flat-bottomed 96-well 
microtiter plates (Becton Dickinson, Oxnard, CA) at a density of
5.5 x 10J cells/well in RPMI 1640 medium containing 5% fetal 
calf serum (FCS; Hyclone Laboratory, Logan, UT), 2 mM  l -  
glutamine, and 100 units/ml penicillin and 100 /xg/ml streptomy­
cin. After overnight incubation (at 37°C) the medium was removed 
and known amounts of rhTNF-« and samples, each containing ac- 
tinomycin D (2 /¿g/well: Sigma), were added. Plates were then fur­
ther incubated for 20  h, after which the supernatant was removed 
and the cells were stained in 0 .1% crystal violet prepared in 1 0 0 % 
methanol for 20  min.
Absorbance was measured at 600 nm by Dynatech MR 600 
Microelisa Auto Reader (Dynatech, Alexandria, VA). The mean ab­
sorbance of eight duplicates was calculated for each sample or con­
trol. Cytotoxicity was calculated as follows: % cytotoxicity =  [1 
-  (absorbance of sample/absorbance of control)] X 100. An un­
paired / test was used to show the significance of cytotoxicity on 
L929 cells with the rabbit sera.
Results
Detection ofTNF-a in IL-1-stimulated PBMC. Cells from 
three donors were incubated with IL-1 (a or ¡3) for 48 h, and 
total TNF-a production was measured by RIA. IL-1 (a or 
f3) at 100 ng/ml induced similar amounts of TNF-a. The time 
course for TNF-a production (figure 1) shows that peak 
production occurred at 12 h and appeared stable for the fol­
lowing 36 h. We next studied PBMC from four donors in­
cubated with IL-1 (a or (3) over a broad dose range (1-100 
ng/ml) for 24 h; results (figure 2) show that TNF-a produc­
tion was maximal after stimulation with 100 ng/ml IL-1 (a 
or /3).
We examined TNF-a production by PBMC stimulated with 
this dose of IL-1 in a larger population of donors (n = 20). 
TNF-a production was above basal levels (unstimulated) af­
ter incubation with either IL-1 a  or -1/3 in 18 donors (figure 
3). We compared the production of TNF-a from these same 
cells stimulated with LPS. As figure 3 also shows, 1 ng/ml
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Figure 1. Time course for the appearance of TNF-a 
produced from IL-l-stimulated PBMC. PBMC were as­
sayed for total (secreted and cell-associated) TNF-a mea­
sured by specific RIA [31]. Results represent mean ±  
SE of three donors. Dotted line indicates detection limit 
of RIA.
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LPS produced a similar amount of TNF-a (mean level, 2260 
±  140 pg/ml) from these 20 donors as did 100 ng/ml IL-la 
or -1 (3.
Effect o f  antihuman IL-1 on LPS-induced TNF-a produc­
tion. As reported previously [27], 0.01 mg/ml of these anti­
bodies neutralize the biologic effects of 100 pg/ml IL-1 (a or 
¡3). Because response to LPS exceeds 100 pg/ml IL-1, we chose
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Figure 2. Total TN F-a produced from PBMC incubated for 24 h 
with IL-1. A, PBMC stimulated with IL-la; B, PBMC stimulated 
with IL-1/3. Total TN F-a was assayed by specific RIA. Dotted lines 
indicate detection limit of RIA.
a higher concentration of immunoglobulin (G + M) (lOOx) 
to attempt to inhibit the TNF response to LPS. TNF-a syn­
thesis was not affected by the presence of both anti-IL-la and 
anti-IL-1/3 in the culture, suggesting that LPS induction of 
TNF-a occurs independent of the autocrine effects of IL-1 (a 
or (3) (table 1).
Production o f TNF-a. in IL-l-stimulated adherent cells. We 
also examined whether TNF-a induced by IL-1 was synthe­
sized exclusively by monocytes and whether lymphocytes 
played a role in this induction. IL-1 (a and /3) was added to 
adherent cells, and the TNF-a response was compared with 
that for PBMC culture. As shown in figure 4, TNF-a produc­
tion by the adherent cells at 12 or 24 h was higher than that 
by PBMC, especially when the stimulant was IL-la (50% 
higher).
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Figure 3. Concentration of total TNF-a in lysates (secreted plus 
cell-associated) of human PBMC from 20 donors incubated with 
a single dose of IL -la  or -1/3 (100 ng/ml). For comparison, 1 ng/ml 
of LPS was used to stimulate the same PBMC. CTRL =  PBMC 
incubated with ultrafiltered RPMI. Dotted line indicates the detec­
tion limit of the RIA.
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Table 1. Effect of combined treatment with rabbit antihuman 
IL-1 a  and antihuman IL-1/3 immunoglobulin on TN F-a produc­
tion in lipopolysaccharide (LPS)-stimulated human peripheral blood 
mononuclear cells (PBMC).
Donor no.
T N F -a  (ng/ml) 9
Normal
immunoglobulin
an ti-IL -la
+
anti-IL-1/3
1 5.83 5.80
2 1.24 1.17
3 4.45 4.93
NOTE. PBM C were incubated in the presence o f  1 mg/ml rabbit immunoglobulin 
(G +  M) and were then stimulated with LPS (100 ng/ml). Total cytokine production 
was measured by radioimmunoassay. Normal immunoglobulin was prepared from 
unimmunized rabbits. LPS-stimulated PBMC from donors 1, 2, and 3 produced 5.66, 
2 .72, and 4.43 ng/ml IL-1 a ,  respectively, in the presence o f  1 mg/ml normal immuno­
globulin.
Effect ofIFN-y on IL-1 ¡3 and TNF-a production induced by 
IL-1 a. In previous studies we demonstrated that IL-1 induced 
IL-1 in PBMC [27] and that IFN-7 inhibited this response 
[30]. In this study, we examined whether IFN-7 had a further 
effect on IL-l-induced TNF-a production. As figure 5 shows, 
coincubation of cells with various concentrations (1-1000 
units/ml) of IFN-7 had no consistent effect on the production 
of IL-la-stimulated TNF-a, whereas IL-l-induced IL-1 pro­
duction was suppressed by >70%.
We also compared the effect of IFN-7 on IL-1 ce- and IL- 
1/3-induced TNF-a production in PBMC from 20 human 
donors (figure 6). Again, IFN-7 had no consistent effect on 
IL-l-induced TNF. IFN-7 itself did not induce TNF-a produc­
tion in these donors, in contrast to previous studies. We at­
tribute this to the removal of endotoxin from the RPMI
Time (h)
Figure 4. Comparison of IL-l-induced TNF-a production between 
PBMC and adherent cells in the time course. Total TNF-a was mea­
sured by the specific RIA. Results represent the mean ±  SE of three 
donors. Dotted line indicates the detection limit of the RIA.
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Figure 5. Effect of IFN -7  on IL-la-induced IL-1 (3 and TNF-a 
production. PBMC from four donors were cultured for 24 h with 
IL-1 a  (100 ng/ml) in the presence (1-1,000 units/ml) or absence of 
IFN-7 . Total IL-1 (3 and TNF-a were determined in the same PBMC 
culture by each specific RIA. Results represent mean ±  SE of four 
donors.
medium by ultrafiltration [33], In addition, the failure of IFN-7 
to enhance TNF production supports the fact that IL-l-induced
TNF-a is not due to contamination by LPS.
No correlation between TNF-a and IL-1 (3 production from
human PBMC after stimulation with IL-1 a. Production of 
TNF-a and IL-1/3 from PBMC was induced by 100 ng/ml IL- 
la  in another group of 29 donors (figure 7). TNF-a produc­
tion was detected in 22 donors (limit of detection, 40 pg/ml; 
range, 100 pg-4.0 ng/ml; mean, 0.45 ±  0.96 ng/ml). On the 
other hand, IL-1 ¡3 production was detected in 24 donors (range, 
80 pg-4.2 ng/ml; mean, 0.81 ± 0.90 ng/ml). It is apparent 
(figure 7) that no correlation exists between TNF and IL-1 
production. These studies support previous observations that 
TNF-a and IL-1 (a or (3) production from PBMC is not linked 
when LPS is used as a stimulus [35].
IL-1 a  induces IL-1 (3 and TNF-a mRNA. As shown in figure 
8A, we could detect mRNA coding for TNF-a after 3 h. Un­
stimulated PBMC also produced small but detectable IL-1 /3 
mRNA that increased after incubation with IL-1 a. Emission 
at 590 nm from the ethidium-stained gel under shortwave 
ultraviolet irradiation demonstrated that the ribosomal bands 
were intact and had about the same intensity in both stimu­
lated and unstimulated PBMC samples (figure 8B). Low lev­
els of TNF-a mRNA may be related to the induction stimulus
1 10  100  1 0 0 0
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Figure 6. Effect of IFN-y on IL-l-stimu- 
lated TNF production in PBMC from 20 
individuals. PBMC were cultured for 24 h 
with 100 ng/ml each IL-1 a  or rhIL-1/3. Cul­
tures were in the presence or absence of 
IFN-y (100 units/ml).
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Figure 7. Comparison of TNF-a production and IL-1/3 produc­
tion in IL-la-treated (100 ng/ml) PBMC from 29 donors. Total 
TN F-a and IL-1/3 were determined by RIA after a 24-h incubation. 
Dotted lines indicate detection limits of the RIA.
provided by IL-1 or the short length of cDNA probe for TNF- 
a  (470 bp).
Induction o f endogenous pyrogen activity during IL-I- 
induced fever. At concentrations of 7 ¿tg/kg, IL-1 a  (figure 
9A) or IL-1/3 (figure 9B) induced biphasic fevers when injected 
intravenously into rabbits. The first peak occurred 40-50 min 
and a second peak 180-220 min after IL-1 injection. The 
plasma from febrile animals 3-3.5 h after IL-1 (a and /3) in­
jection was passively transferred to new rabbits, producing 
brief, monophasic fevers in the recipients (figure 9A, B, in­
sets). These monophasic fevers represent typical endogenous 
pyrogen fever patterns [1-4]. By contrast, plasma from saline- 
injected rabbits produced no change in rectal temperatures 
(figure 9A, inset).
Appearance ofTNF-like activity in the serum o f IL-J-injected 
rabbits. Rabbit serum collected during the second febrile 
peak induced by IL-1 was cytotoxic to L929 cells (figure 10). 
This effect was not due to the serum because the same amount 
of control preinjected serum alone induced little cytotoxic­
ity Even normal rabbit serum (10%) added to various con­
centrations of rhTNF-a did not change the sensitivity to the 
cytotoxic effect of TNF-a (data not shown).
A B
Figure 8 . A, IL-1 a -induced TNF-a and IL-1/3 mRNA 
from PBMC. RNA was extracted from cells after 3 h 
of incubation with (+) or without ( - )  100 ng/ml IL-1 a. 
The blot was hybridized with a labeled probe for TNF- 
a, autoradiographed, and then stripped. The blot was 
hybridized again with labeled probe for IL-1/3. Samples 
1 and 2 were from two different donors. B, Ethidium 
bromide-stained agarose gels corresponding to donor 
1 and 2 .
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Figure 9. Febrile responses of rabbits injected intravenously with 
7 /xg/kg IL-1 a: (A) and -1/3 (B). Each point represents the mean of 
three rabbits. CTRL =  rabbit receiving saline. At the times indi­
cated by arrows, febrile rabbits were bled and the plasma (10 ml) 
was injected into recipient rabbits (insets). Inset in A also shows 
the reponse of the recipients to the control plasma prepared from 
rabbits injected with saline.
We next studied the time of appearance of cytotoxic activ­
ity in the circulation of IL-l-injected rabbits. Three hours af­
ter IL-1 injection, serum from these animals induced 80%-90% 
cytotoxicity on L929 cells (figure 11). Interestingly, the cyto­
toxicity of the serum from the IL-1/3-injected rabbits decreased 
in the circulation by 5 h, while most of the IL-la-induced 
cytotoxic activity was still elevated after 5 h (figure 11).
Discussion
Numerous studies have demonstrated that endotoxin induces 
the production of IL-1 and TNF in macrophages and mono­
cytes and that these cytokines are probably responsible for
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Figure 10. Cytotoxic activity on L929 cells of sera obtained from 
two rabbits 3-3.5 h after injection of 7 /xg/kg IL -la  and -1/3. L929 
cells were treated overnight with dilutions of serum in the presence 
of actinomycin D. CTRL = serum taken before injection of IL-1. 
Results represent mean ±  SD of triplicate cells.
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Figure 11. Time course for the appearance of cytotoxic activity 
in rabbit sera after injection of IL-1 a  or -1/3 (9 /xg/kg each). Sera 
were assayed at a 25% concentration for TNF-like activity using 
cytotoxicity of L929 cells. Results represent mean ±  SE of eight 
wells of the L929 cells. * =  significance of cytotoxicity between 
IL-1 a -  and IL-l/3-induced sera after 5 h (P <  .001).
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the multiple acute-phase responses associated with sepsis and 
bacterial toxemias [36, 37]. An antibody, highly specific 
against murine TNF-a, has been shown to protect BALB/c 
mice against the lethal effects of E. coli endotoxin [38]. Simi­
larly, a goat anti-TNF antibody has been reported to inhibit 
TNF production induced by endotoxin and to protect rabbits 
from endotoxin shock [39].
Both in vivo and in vitro, endotoxin-stimulated IL-1 and 
TNF may reach local or systemic levels that themselves may 
affect the production and activity of these cytokines. In this 
regard it has been reported that <1 ptg/kg of TNF-a can in­
duce monophasic fevers in rabbits; if the dose of TNF-a is 
increased 10-fold, IL-1—like activity is detected in plasma 3.5 
h after TNF injection [12]. This observation was confirmed 
in vitro by the ability of TNF to induce IL-1 in human PBMC 
[12] and cultured endothelial cells [26]. Philip and Epstein 
[40] also reported that TNF alone and IFN-a and IFN-y can 
enhance IL-1 production.
IL-1 induces IL-1 gene expression and synthesis in human 
PBMC, smooth muscle cells, and endothelial cells. Each form 
of IL-1 induces transcription of mRNA for either form within
1 h [27-29]. In this study we show another effect of IL-1: the 
induction of TNF. TNF induction by IL-1 (a or /3) in cultured 
human PBMC was demonstrated by Northern blot analysis 
of TNF-o: mRNA and by measurement of TNF immunoreac- 
tive protein. Accumulation of TNF-a mRNA might be due 
to the activation of transcription or increased stability of the 
mRNA.
Our results are based on immunoreactive TNF-a. The differ­
ence between the bioactivity and immunoreactivity of TNF- 
a  has been reported recently [41-43]. Low levels of cytotoxic 
bioactivity of TNF, compared with that as measured by RIA, 
may be due to inactive forms, inhibitors, or unstable forms 
of receptor-ligand binding. High levels of cytotoxic activity 
may be due to lymphotoxin. In our previous studies [31], how­
ever, a correlation was found in PBMC cultures between the 
levels of TNF-a as measured by RIA and TNF activity as de­
tected by a cytotoxic effect on L929 cells. The correlation 
coefficient was 0.89 over a wide detection range (100 pg-100 
ng/ml). However, we cannot rule out that IL-1 also induces 
lymphotoxin in PBMC.
We next considered the possibility that because LPS stimu­
lates IL-1 production, part of the TNF responses to LPS might 
be via IL-1. When we measured the amount of immunoreac­
tive IL-1 (a and (3) [32, 35] induced by LPS stimulation of 
PBMC, levels of either form were consistently in the range 
of 3-10 ng/ml. However, TNF-a production by PBMC stimu­
lated with these concentrations of IL-1 (a or (3) ranged from 
100 to 250 pg/ml (figure 2), far below the amount of TNF- 
a  (2260 ±  140 pg/ml) synthesized in response to LPS.
In addition, coincubation of PBMC with antibodies directed 
against both forms of IL-1 did not affect TNF-a production 
induced by 100 ng/ml LPS. At the concentration used (1 
mg/ml), these antibodies previously have been shown to neu­
tralize 10 ng/ml of IL-1 (a or 0) [27] and should have Been 
sufficient to neutralize the amount of IL-1 a  (table 1) induced 
by the highest concentration of LPS studied here. We con­
clude from these data that the levels of IL-1 induced by LPS 
are not high enough to account for the concomitant synthesis 
of TNF-a. These results make it highly unlikely that TNF 
synthesis in response to LPS is mediated by an autocrine effect
of IL-1.
Relatively greater amounts of TNF-a were synthesized by 
IL-l-stimulated adherent cells compared with PBMC, indi­
cating that this TNF-a response is due mainly to esterase posi­
tive cells, in most cases monocytes. The greater production 
of TNF-a in the adherent cells might be attributed to an in­
crease in IL-1 binding to the adherent cells, thereby possibly 
reducing the binding of IL-1 to lymphocytes, or an elimina­
tion of an inhibitory role by lymphocytes on monocyte TNF 
synthesis. Because IFN-y has been reported to have both 
stimulatory and inhibitory effects on cytokine-induced cyto­
kine production [12, 30, 43], we studied its effects on IL-1—in­
duced TNF-a production. However, IFN-y reduces LPS- and 
IL-l-induced PGE: release from human cells [44]. Further­
more, IL-l-induced IL-1 production is significantly reduced 
by coincubation with IFN-y [30], whereas IFN-y consistently 
increases the IL-1 in response to LPS and other microbial 
agents. In the present study, we did not observe a consistent 
effect of IFN-y on IL-l-induced TNF-a production.
The separate effects of IFN-y on IL-l-induced IL-1 produc­
tion versus TNF-a production suggest that IL-1 synthesis is 
regulated differently from that of TNF-a. This observation 
is supported by our data showing no apparent linkage of IL- 
1/3 and TNF-a production by PBMC of 29 donors. Burchett 
et al. [45] reported that the production of TNF-a and IL-1 
by LPS-stimulated monocytes was differently regulated by 
IFN-y. These observations are also supported by the known 
differences that exist in the regulation of gene expression and 
protein synthesis for IL-1 and TNF-a.
The biologic rationale for the mutual induction of IL-1 and 
TNF-a is still unclear. However, because IL-1 has been shown 
to induce hypotension [46] and the regression of some tumors 
in vivo [47], the ability of IL-1 to induce circulating TNF- 
like activity as well as IL-1 may provide a mechanism for this 
effect. Recently, it was reported that prolonged daily injec­
tion of IL-1 into monkeys induced a circulatory TNF-like ac­
tivity that was thought to suppress hematopoiesis [48]. The 
synergism of IL-1 and TNF-a has been reported on an­
tiproliferative activity on the A375 melanoma cell line [49], 
augmentation of PGE: production from human lung fibro­
blasts [50], and cytotoxicity of chondrosarcoma, fibrosar­
coma, and carcinoma lines [51]. TNF-a also potentiates the 
effects of IL-1 on rat pancreatic islets of Langerhans insulin 
production [52], on rat bone resorption [53], in a model of 
IL-l-induced local Shwartzman reaction [54], and in the in­
duction of a shock-like state in rabbits [46]. Thus, the induc­
tion of one or more cytokines (e.g., TNF-a) by another
222 Ikejima et al JID 1990; 162 (July)
cytokine (e.g., IL-1) appears more efficient in inducing cyto­
toxicity and inflammation than synthesizing larger amount of 
either monokine alone.
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